MARKETS
Markets

Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

Jul 23, 2026 · 08:04 AM ET· updated 2h ago

First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast Track designation,

Share
Why It Matters

A medicine company started testing a new sleep apnea drug on real people—an important step toward finding out if it works. Watch for updates on how many people join the test and whether early results look good, which tells you if the company is making progress.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.